The objective of this study was to assess the clinical and pathological characteristics, as well as the oncological outcomes, of Brenner tumors (BTs). The assessment was conducted on the information of 63 patients diagnosed with Brenner Tumor, which was obtained from both the oncology clinic database and pathology reports spanning the time period from 2002 to 2022. The patients’ ages in the study had a median of 57 years, ranging from 43 to 83 years. Median (range) tumor size was 10 (0.75–165) mm. Out of the total number of patients, 60 individuals (95.2%) had benign tumors, while the remaining 3 (4.8%) were diagnosed with malign tumors. No borderline tumors were detected among the patients. A mixed tumor, comprising both a borderline tumor and other ovarian pathology, was found in 7 cases, accounting for 11.1%. Brenner tumors are infrequent and typically identified coincidentally. Malign Brenner Tumors (MBTs) receive similar management as epithelial neoplasms. Given the uncommon nature of these tumors, the appropriateness of lymphadenectomy and optimal chemotherapy protocols remains a subject of debate.